RCUS earnings: real EPS beat/miss history, analyst consensus Buy, P/E -9.46. Updated 2026-07-23.
Arcus Biosciences (RCUS) Research Hub
Arcus Biosciences (RCUS) trades on NYSE, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 24.59 USD (-13.69%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -9.46, market cap 2.93B. This hub links to the full technical, earnings and options research available for RCUS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NYSE, US |
| Last close | 24.59 USD (-13.69%) |
| 52-week range | 23.6 USD – 31.74 USD |
| Trend regime | Range |
| 14-day RSI | 32.9 (Bearish) |
| Trailing P/E | -9.46 |
| Market cap | 2.93B |
| Dividend yield | 0.00% |
Available research for RCUS
Covered Call on RCUS: how it works, illustrative setup around the real 24.59 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RCUS: how it works, illustrative setup around the real 24.59 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RCUS: how it works, illustrative setup around the real 24.59 USD price, max profit/loss, breakeven and when to use it. Educational.
RCUS technical analysis: range, last 24.59 USD, RSI 32.9, 52w range 23.6 USD–31.74 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is RCUS in?
Arcus Biosciences (RCUS) is classified under Healthcare (Biotechnology), listed on NYSE, US.
Is RCUS in an uptrend or downtrend?
As of 2026-09-11, RCUS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RCUS's trailing P/E ratio?
RCUS's trailing P/E is -9.46, with a market cap of 2.93B. See the earnings research page for full valuation detail.